Global Overactive Bladder Treatment Market - 2022-2029

Market Overview

The global overactive bladder treatment market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 3.6% during the forecast period (2022-2029).

An overactive bladder is a group of urinary syndromes characterized by sudden, involuntary muscle contraction in the wall of the urinary bladder. This results in an immediate, compelling need to urinate that is difficult to suppress, even though the bladder may only contain a small amount of urine. Other symptoms include nocturia or urinary incontinence.

Market Dynamics

The major factors driving the global overactive bladder treatment market are the rise in the prevalence of overactive bladder, growth in the geriatric population, an increase in neurological disorders and obesity, and an increase in R&D by major market players.

The increasing research and development investments and rising technological advancements are expected to drive the market's growth.

The overactive bladder treatment market is driven by rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of overactive bladder patients and improvements in novel products using the latest technology in medical infrastructure in emerging markets.

Furthermore, prominent key market players and manufacturers are continuously working on new research and development and increasing investments to develop new drugs and therapies, such as neuromuscular blocking agents with innovative mechanisms of action. A rise in investment and R&D boost market growth. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, research studies, and rising awareness initiatives about these Overactive Bladder Treatments contribute to the market's growth. For instance, in February 2021, Allergan, a company of AbbVie, announced the approval of its BOTOX for detrusor overactivity (bladder muscle) related to the neurologic condition in patients aged five years or older who have intolerability to anticholinergic medicines.

Side effects associated with overactive bladder treatments are expected to hamper the market's growth.

Several side effects are observed after using antimuscarinic medicines, such as constipation, dry mouth, blurred vision, urinary tract infection, itchy or dry eyes, drowsiness and urinary retention. Sometimes people experience irregular heart rhythms that can be life-threatening, but their chances are very rare. Drinking water due to dry mouth can aggravate the overactive bladder symptoms.

Lack of awareness is also a leading factor restraining the market's growth. In low-income countries, people are unaware of overactive bladder prevalence, and the unavailability of reimbursement scenarios hinders the market's growth.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The overactive bladder treatment market has experienced huge profits due to COVID. In covid patients, bladder-related problems such as overactive bladder were also observed. COVID affected the bladders of patients. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in July 2022, Urovant Sciences announced its license agreement with Pierre Fabre Medicament for Vibegron commercialization for overactive bladder treatment in European Areas.

Segment Analysis

The nerve stimulation segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The nerve stimulation treatment segment is the highest market holder in the global overactive bladder treatment market. The global overactive bladder treatment market is segmented based on treatment type as nerve stimulation, behavioral intervention, medications, botulinum toxin injections and surgery. The nerve stimulation segment is the largest market shareholder due to its inherent advantages over other treatments, increasing technological advancements and novel product launches.

Neuromodulation or nerve stimulation is an effective way to treat an overactive bladder. An electrode is implanted under the skin to stimulate nerves with electricity around the bladder. The electric signals traveling from the bladder to the brain are blocked with electricity reducing the symptoms of an overactive bladder are blocked. These therapies are of two types: sacral neuromodulation and percutaneous tibial nerve stimulation.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in April 2021, Medtronic, the medical technology company, announced receiving approval from the United States Food and Drug Administration to continue the investigational device exemption trial for evaluating its implantable tibial neuromodulation device, an internally developed therapy specially developed for bladder incontinence symptom's relief.

Geographical Analysis

North America holds the largest market share in the global overactive bladder treatment market.

North America dominates the global overactive bladder treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US and the growing geriatric population. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of overactive bladder medications and neurostimulation therapies, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region contribute to the overactive bladder treatment market growth.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in Jan 2021, Astellas Phrma Inc. announced its priority review acceptance by the United States Food and Drugs Administration for Mirabegron or Myrbetriq tablets, its novel drug application for neurogenic detrusor overactivity treatment in pediatric patients.

Competitive Landscape

The overactive bladder treatment market is highly competitive with local and global companies' presence. Medtronic, Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., Teva Pharmaceutical Industries Limited, AbbVie Inc., Accord Healthcare Inc., Laborie, Macleods Pharmaceuticals Ltd, Urovant Sciences and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in November 2022, Urovant Sciences, Sumitovant Biopharma Ltd's subsidiary, announced its partnership with Thinx Inc, an incontinence and period underwear brand. They launched "Time To Go," an educational campaign to educate people about overactive bladders, such as their symptoms and how to manage them.

Medtronic

Overview: Medtronic is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Medtronic Bladder Control Therapy: This is a therapy in which the InterStim system delivers sacral neuromodulation. It utilizes an implantable device to deliver electrical pulses to sacral nerves near the tailbone hence creating miscommunication between sacral nerves and the brain to control the symptoms.

Key Development: In February 2022, Medtronic plc, a healthcare technology company, announced that its InterStim X got approved by the United States Food and Drug Administration. This new generation of InterStim recharge-free device is an advanced therapy system to provide sacral neuromodulation therapy for bowel and bladder incontinence,

The global overactive bladder treatment market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.